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2363people in the general population (4). HCM is a clinically
and genetically heterogenous disease, associated with
>1,500 mutations in $11 major genes (and a variety of
other susceptibility genes with lesser evidence for path-
ogenicity), encoding proteins of the cardiac sarcomere,
adjacent Z disk, and calcium handling (5).
Although HCM is associated with substantial diversity
in morphological expression (6), clinical diagnosis usually
occurs with recognition of the characteristic disease
phenotype, that is, left ventricular (LV) hypertrophy
without chamber dilatation in the absence of another
cardiac or systemic disease capable of producing the
magnitude of hypertrophy evident (1,6). Neither systolic
anterior motion of the mitral valve, hyperdynamic LV
function, or identiﬁcation of pathogenic sarcomere mu-
tations is obligatory for the clinical diagnosis of HCM (2).
Atrial ﬁbrillation is a common cause of morbidity in HCM,
occurring in z20% of patients, although usually after
30 years of age (1,2). Notably, the clinical presentation
and course are diverse, with unexpected sudden death in
the young the most visible disease complication.
SUDDEN DEATH RISK
A major impetus in HCM has been the identiﬁcation of
those patients at increased risk for sudden death. Indeed, a
risk-stratiﬁcation algorithm has been largely effective in
identifying those people at highest risk who are eligible
for primary prevention of sudden death with an implant-
able cardioverter-deﬁbrillator (ICD) (7–10), thereby mark-
edly reducing HCM-related mortality to 0.5% per year (7).
Sudden death events are attributable to potentially lethal
ventricular tachyarrhythmias (ventricular tachycardia/
ventricular ﬁbrillation) and usually occur in the presence
of $1 the major risk markers (appropriate ICD interven-
tions of 4% per year in patients implanted for primary
prevention) (7–10). Some HCM patients may nevertheless
die suddenly in the absence of all conventional risk
factors (0.6% per year in non-ICD populations) (7).
Indeed, in the presence of underlying (and often
unsuspected) HCM, participation in high-intensity com-
petitive sports may itself promote ventricular tachy-
cardia/ventricular ﬁbrillation and act as a potent (yet
modiﬁable) independent risk factor, even in the absence
of conventional risk markers intrinsic to the disease pro-
cess (3,7,11,12). Notably, the underlying electrophysiolog-
ical substrate in HCM is unpredictable (1,2,7–10) and
potentially subject to instability by interaction with phys-
iological stresses inherent in athletic training and compe-
tition, including alternations in hydration, blood volume,
and electrolytes, as well as the catecholamine surge.
Given these principles, it is difﬁcult to apply conventional
risk-stratiﬁcation strategies to make reliable eligibility de-
cisions speciﬁcally for aspiring competitive athletes withHCM. The estimation of risk level based on phenotypic
expression (e.g., speciﬁc LV wall thickness or LV outﬂow
tract gradient) or other aspects of the clinical proﬁle is a
highly problematic endeavor. Such considerations are
inﬂuenced by the morphological diversity of HCM and the
unpredictable instability of the myocardial substrate, as
well as the additive risk created by intense training and
competition in susceptible patients with HCM (3). There-
fore, in HCM, the most common cause of sudden death in
young athletes (1–3), engagement in intense competitive
sports is itself an acknowledged modiﬁable risk factor (1–3).
These observations necessitate conservative and
prudent recommendations regarding sports eligibility
applied in a homogeneous fashion across the broad HCM
disease spectrum. This may unavoidably result in rec-
ommendations for disqualiﬁcation in some athletes with
HCM probably at low risk and unlikely to ever experience
sudden death, who could potentially compete and train
safely. Notably, the present disqualiﬁcation/eligibility
guidelines for competitive athletes with HCM do not
differ measurably from those previously stated in the 36th
Bethesda Conference (11), because alternative new data or
insights have not emerged sufﬁcient to substantially
alter the recommendations.
On the other hand, the present American Heart Asso-
ciation/American College of Cardiology recommendations
do not strictly exclude in absolute terms fully informed
athletes from participating in competitive athletic pro-
grams as long as such a decision is ultimately made
in concert with their physician and third-party interests
(e.g., high schools and colleges). Although this expert
consensus report serves as a prudent guideline regarding
sports eligibility or disqualiﬁcation, there will always be
tolerance in the system for some degree of ﬂexibility,
individual responsibility, and choice in making these
decisions for individual student athlete-patients.
Genotype Positive–Phenotype Negative
An increasing number of HCM family members are recog-
nized with documented pathogenic (disease-causing)
sarcomere mutations, but in the absence of a clinical
HCMphenotype (i.e., LV hypertrophy) (5,13). Such patients
have been identiﬁed at a broad range of ages, although they
are most commonly adolescents and young adults, and
some wish to engage in competitive sports.
Spontaneous conversion to LV hypertrophy in this
subset appears to occur most often in adolescence be-
tween 12 and 20 years of age (1,13) but has also been
observed in midlife and beyond (14,15). Nevertheless, such
changes are unpredictable, and some genetically affected
people will probably never develop the HCM phenotype.
Spontaneous morphological conversions are not usually
accompanied by cardiac symptoms, disease progression,
or events (1,2,13–15). However, once LV hypertrophy
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2364evolves, that person may theoretically be subject to an
unstable HCM electrophysiological substrate.
With negative or ambiguous genetic test results, poten-
tially affected relatives can nevertheless be suspected
clinically by the presence of several echocardiographic
or cardiovascular magnetic resonance (CMR) ﬁndings in
the nonhypertrophied myocardium, that is, blood-ﬁlled
crypts, elongated mitral valve leaﬂets, diastolic dysfunc-
tion, and myocardial scarring (5,16–19). At present, the risk
for sudden death in gene-positive–phenotype-negative
family members appears to be extremely low and likely
no different from the risk in the general population of
the same age without heart disease (5,20). CMR imaging
is also an important consideration in family members who
are gene positive and judged to be phenotype negative
based on echocardiography, because areas of segmental
LV hypertrophy may be detected only by CMR, particularly
in the anterolateral free wall and apex (6,21).
Recommendations
1. Participation in competitive athletics for asymptom-
atic, genotype-positiveHCMpatientswithout evidence
of LV hypertrophy by 2-dimensional echocardiography
and CMR is reasonable, particularly in the absence of
a family history of HCM-related sudden death (Class
IIa; Level of Evidence C).
2. Athletes with a probable or unequivocal clinical
expression and diagnosis of HCM (ie, with the disease
phenotype of LV hypertrophy) should not participate
inmost competitive sports, with the exception of those
of low intensity (class IA sports) (see “Classiﬁcation
of Sport” [22]). This recommendation is independent
of age, sex, magnitude of LV hypertrophy, particular
sarcomere mutation, presence or absence of LV
outﬂow obstruction (at rest or with physiological ex-
ercise), absence of prior cardiac symptoms, presence
or absence of late gadolinium enhancement (ﬁbrosis)
on CMR, and whether major interventions such as
surgical myectomy or alcohol ablation have been
performed previously (Class III; Level of Evidence C).
3. Pharmacological agents (e.g., b-blockers) to control
cardiac-related symptoms or ventricular tachyar-
rhythmias should not be administered for the sole
purpose of permitting participation in high-intensity
sports. Notably, such drugs may also be inconsistent
with maximal physical performance in most sports
(Class III; Level of Evidence C).
4. Prophylactic ICDs should not be placed in athlete-
patients with HCM for the sole or primary purpose
of permitting participation in high-intensity sports
competition because of the possibility of device-related
complications. ICD indications for competitive athletes
with HCM should not differ from those in nonathlete
patients with HCM (Class III; Level of Evidence B).Other recommendations for sports participation in
patients with HCM and ICDs can be found in the
Task Force 9 report on “Arrhythmias and Conduction
Defects” (23).
LV NONCOMPACTION
LV noncompaction (LVNC) is an uncommon and recently
recognized cardiac disease with sporadic or familial
occurrence (24). Its true incidence and prevalence are
not known, in part because of difﬁculty in making the
diagnosis and lack of agreement on criteria, as well as its
heterogeneous clinical spectrum and usual requirement
of CMR for reliable diagnosis. Furthermore, its clinical
presentation and implications differ with respect to
genetic pathogenesis, race/ethnic origin, presence in iso-
lation or in association with other diseases, or depen-
ding on the presence or absence of right ventricular
involvement (25).
The natural history of LVNC remains incompletely
resolved because of its relatively recent recognition with
a short available follow-up period (26–34). The clinical
expression of LVNC is variable, even within families: with
or without symptoms, heart failure, atrial and ventricular
arrhythmias or preexcitatory pathways, thromboembolic
events, or sudden death (35). While LVNC patients with
heart failure and systolic dysfunction, thromboembolic
events, and sudden cardiac death have been reported
(26,31,33,34), many uncomplicated cases are less likely
to be recognized or appear in the literature (34). Risk
for adverse consequences, including mortality, presently
appear to be largely associated with LV systolic dysfunc-
tion or ventricular tachyarrhythmias (34).
Few competitive athletes with LVNC have been
reported clinically, and therefore, the consequences of
LVNC in this speciﬁc population are unknown. Further-
more, to date, forensic registries of sudden deaths in
young athletes do not include LVNC as a cause (3),
although the diagnosis may still be widely underappre-
ciated in the routine medical examiner autopsy setting.
Therefore, given the lack of long-term follow-up studies
and other obstacles, it is not yet possible to reliably apply
risk-stratiﬁcation strategies to new patients (or athletes)
with LVNC. This is not unlike the situation with other
uncommon myocardial diseases for which few data con-
cerning sudden death risk during competitive sports are
available (e.g., dilated cardiomyopathy [DCM] or inﬁltra-
tive diseases). Therefore, the complete natural history
of noncompacted ventricular myocardium remains
unresolved.
A variety of inheritance patterns have been reported
(ie, autosomal dominant, autosomal recessive, and X-
linked) (24,27). Mutations in genes encoding sarcomeric
proteins, which previously have been implicated in the
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2365pathogenesis of HCM and DCM, have also been identiﬁed
in patients with isolated LVNC (24,27). These observa-
tions suggest that LVNC shares genetic overlap with other
cardiomyopathies, and indeed, some individual patients
have been reported with morphological features consis-
tent with both HCM and LVNC (32).
LVNC is thought to be caused by the intrauterine arrest
of the compaction process of the primordial embryonic
myocardium. Diagnosis is considered in the presence of
a 2-layered LV chamber that consists of noncompacted
trabeculations with intertrabecular recesses layered on
top of the typical compacted myocardium, with or with-
out systolic dysfunction. The trabeculated layer is pre-
dominantly conﬁned to the distal and mid portions of
the LV chamber, sparing the base. Currently, there are
no universally accepted criteria or guidelines for the
morphological diagnosis of LVNC, although a ratio of
noncompacted to compacted myocardium >2.1:1 at end
systole (echocardiography) or >2.3:1 in end diastole
(CMR) have been proposed (30,32,36). It is uncertain how
athletic training may alter those deﬁnitions (28,29) or
the frequency of LVNC-appearing morphology in a
normal athlete population. CMR is generally superior to
echocardiography for identiﬁcation of regions of non-
compacted myocardium and for more deﬁnitive diagnosis
of LVNC.
Recommendations
1. Until more clinical information is available, partici-
pation in competitive sports may be considered for
asymptomatic patients with a diagnosis of LVNC and
normal systolic function, without important ventric-
ular tachyarrhythmias on ambulatory monitoring
or exercise testing, and speciﬁcally with no prior
history of unexplained syncope (Class IIb; Level of
Evidence C).
2. Athletes with an unequivocal diagnosis of LVNC and
impaired systolic function or important atrial or ven-
tricular tachyarrhythmias on ambulatory monitoring
or exercise testing (or with a history of syncope)
should not participate in competitive sports, with the
possible exception of low-intensity class 1A sports,
at least until more clinical information is available
(Class III; Level of Evidence C).
OTHER MYOCARDIAL DISEASES
A number of other uncommon diseases of the myocar-
dium deserve consideration as potential causes of sudden
death in athletes. These include DCM (attributable to
a variety of causes, including genetic), primary non-
hypertrophied restrictive cardiomyopathy, and systemic
inﬁltrative diseases with secondary cardiac involvement,
such as sarcoidosis. Few data are available at presentregarding the relative risks of athletic training and
competition in athletes with these myocardial diseases.
It is important to differentiate physiological LV
enlargement caused by systematic training from patho-
logical DCM. Long-term aerobic athletic training can lead
to cardiac morphological changes, including increased LV
cavity dimension and calculated mass. Increased cavity
size can produce a higher stroke volume, and thus, the
ejection fraction at rest may be in the low-normal to
mildly reduced range. Up to 15% of trained athletes will
have substantial enlargement of the LV cavity, with end-
diastolic dimensions up to 70 mm in men and 66 mm in
women (37,38). Ejection fraction in trained athletes has
been shown to be as low as 45% (37). Whether newer
imaging techniques such as myocardial Doppler tissue
imaging, strain imaging, or contrast-CMR scanning can
differentiate patients with borderline LV enlargement and
low-normal or mildly reduced ejection fraction from DCM
is unresolved.
It is unclear whether asymptomatic patients with DCM
are at risk for sudden death during competitive athletics,
because ventricular tachyarrhythmias are most common
in patients with more advanced disease, that is, with
cardiac symptoms and lower ejection fraction.
Recommendations
1. Symptomatic athletes with DCM, primary non-
hypertrophied restrictive cardiomyopathy, and inﬁl-
trative cardiac myopathies should not participate in
most competitive sports, with the possible exception
of low-intensity (class 1A sports) in selected cases, at
least until more information is available (Class III;
Level of Evidence C).
MYOCARDITIS
General Considerations
Myocarditis commonly presents with disproportionate
dyspnea on exertion, chest pain, and arrhythmias. It can
also present as an acute myocardial infarction–like syn-
drome with sudden death in the presence of normal
epicardial coronary arteries (39–44). The contribution
of myocarditis to cardiovascular sudden death varies
signiﬁcantly with age, causing cardiovascular sudden
death inz2% of infants, 5% of children, and 4% to 7.5% of
athletes (3,40). Higher rates of myocarditis are occasion-
ally reported in postmortem studies from general pop-
ulations younger than 35 to 40 years of age (41). Most
cardiovascular sudden deaths attributable to myocarditis
occur in males (42), and in some cases, myocarditis results
in sudden death without antecedent symptoms or
macroscopic cardiac abnormalities (40,42,43).
The data linking myocarditis to sudden death are strong
and include autopsy studies and experimental myocarditis
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associated with sudden death in a cohort of U.S. military
recruits, with the most frequent underlying cause being
myocarditis (44). Case series of sudden death in athletes
have established myocarditis as a signiﬁcant risk in this
speciﬁc group (3). In a murine model of coxsackie B3
myocarditis, 60 minutes of swimming daily increased viral
titers, worsened cardiomyopathy, and increased the like-
lihood of death (45). In a chronic autoimmune myocarditis
model, humeral and cellular immunity directed against
heart tissues increased with treadmill exercise (46). Unlike
heart failure, the risk of sudden death caused by myocar-
ditis does not appear to correlate with the severity of
myocardial inﬂammation (40). Sudden death has been
observed occasionally after myopericarditis in association
with normal LV function (47–49).
The pathogenesis of myocarditis consists of 3 over-
lapping phases: acute injury, often caused by a virus; the
host innate and acquired immunologic response; and
ﬁnally, recovery or a transition to scar and DCM. There is
rarely a clear distinction between these phases clinically.
The initial injury may cause an acute DCM with contractile
impairment mediated by cytokines generated by the local
inﬂammatory process. Several months later, the same
dilated ventricle may have poor contractility caused by
diffuse scar, with little or no inﬂammation. The transition
from acute myocarditis to chronic DCM probably occurs
over months, with substantial individual variability (50).
In clinical practice, myocarditis is often suspected but
infrequently conﬁrmed by endomyocardial biopsy, which
creates a need for noninvasive diagnostic criteria to guide
recommendations for athletic participation. For the pur-
poses of this document, probable acute myocarditis is
diagnosed when both of the following criteria are met:
1. A clinical syndrome that includes acute heart failure,
angina-type chest pain, ormyopericarditis of<3months’
duration.
2. An otherwise unexplained elevation in serum troponin;
electrocardiographic features of cardiac ischemia;
otherwise unexplained high-degree AV block or
arrhythmias; wall motion abnormalities; pericardial
effusion on echocardiography or CMR imaging. Addi-
tional CMR ﬁndings that suggest myocarditis in the
acute clinical setting include characteristic alterations
in tissue signal on T2- or T1-weighted images and the
presence of late gadolinium enhancement (LGE).
CMR features that may be used to diagnose probable
myocarditis include a regional increase in water con-
tent visible on T2-weighted images, an increase in regional
contrast-enhanced T1-weighted epicardial or mid-
myocardial signal obtained within a few minutes of the
gadolinium bolus (“hyperemia” or “early-enhancement”sequences), and epicardial or midmyocardial LGE (51). A
regional and reversible increase in wall thickness that in-
dicates myocardial edema is a supportive ﬁnding of acute
myocarditis. Myocardial ﬁbrosis, the late sequelae of
myocarditis characteristic of DCM, may be indistinguish-
able from active myocarditis on LGE sequences.
The sensitivity of CMR for myocarditis also decreases a
few weeks after the initial illness (51).
Although acute myocarditis is associated with the
characteristic ﬁndings of myocardial injury described in
the diagnostic criteria above, there is no sensitive or
speciﬁc test that can determine when the inﬂammatory
process ends. DCM associated with acute myocarditis
often resolves over 6 to 12 months. Athletes in whom the
ﬁndings of acute inﬂammation have resolved may still
have a risk of arrhythmias related to the resultant
myocardial scar. The presence of LGE may convey a
heightened risk for arrhythmias (52). The interval be-
tween initial assessment and retesting before resumption
of sports will vary depending on the severity of the initial
illness. A reasonable minimum interval for retesting
based on experimental models is 3 to 6 months. The rec-
ommendations presented here recognize these gaps in
knowledge and the need for additional clinical research
to reﬁne risk stratiﬁcation for sudden death after acute
myocarditis.
A diagnosis of myocarditis by biopsy is usually not
required to guide clinical management, but a biopsy may
be considered in select cases according to current pro-
fessional society recommendations from the American
Heart Association, American College of Cardiology, and
European Society of Cardiology (53). Conﬁrmation of
myocarditis by endomyocardial biopsy creates a deﬁni-
tive diagnosis.
Recommendations
1. Before returning to competitive sports, athletes who
initially present with an acute clinical syndrome
consistent with myocarditis should undergo a resting
echocardiogram, 24-hour Holter monitoring, and an
exercise ECG no less than 3 to 6 months after the
initial illness (Class I; Level of Evidence C).
2. It is reasonable that athletes resume training and
competition if all of the following criteria are met
(Class IIa; Level of Evidence C):
a. Ventricular systolic function has returned to the
normal range.
b. Serum markers of myocardial injury, inﬂammation,
and heart failure have normalized.
c. Clinically relevant arrhythmias such as frequent
or complex repetitive forms of ventricular or sup-
raventricular ectopic activity are absent on Holter
monitor and graded exercise ECGs.
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2367At present, it is unresolved whether resolution of
myocarditis-related LGE should be required to permit
return to competitive sports.
3. Athletes with probable or deﬁnite myocarditis should
not participate in competitive sports while active
inﬂammation is present. This recommendation is
independent of age, gender, and LV function (Class III;
Level of Evidence C).
ARRHYTHMOGENIC RIGHT VENTRICULAR
CARDIOMYOPATHY
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
is a cause of sudden death in young people and athletes,
particularly in the northeastern (Veneto) region of Italy
(54), but is seemingly less common in the United States
(3). ARVC is characterized by a broad phenotypic spec-
trum and characteristically by loss of myocytes in the
right ventricular myocardium, with fatty or ﬁbrofatty
replacement, which results in segmental or diffuse wall
thinning, but there is also frequent involvement of the LV
and an association with myocarditis (55). Genetics studies
have demonstrated that ARVC is a desmosomal cardio-
myopathy that results from genetically defective cell-
adhesion proteins such as plakoglobin, plakophilin-2,
desmoplakin, desmocollin-2, and desmoglein-2 (56,57).
Clinical diagnosis can be challenging but relies largely on
familial occurrence, left bundle-branch pattern ventricular
tachyarrhythmias, ECG ﬁndings of T-wave inversion in
precordial leads V1 through V3, and epsilon waves, as well
as right ventricular dilation or segmental wall motion ab-
normalities, aneurysm formation, or fatty deposition in the
right ventricular wall identiﬁed with CMR imaging if sub-
stantial and unequivocal (or by biopsy tissue analysis).
Diagnostic criteria for ARVC have been revised and upda-
ted and now include quantitative variables (58).
These criteria include global or regional structural
dysfunction, as documented by echocardiography or
CMR, biopsy abnormalities, ECG repolarization or depo-
larization abnormalities, arrhythmias, and family history.
Each of these criteria is separated into major and minor
criteria based on the severity of the ﬁnding. Patients meet
an ARVC diagnosis if they possess 2 major, or 1 major and
2 minor, or 4 minor criteria. Borderline patients are those
with 1 major and 1 minor criterion or 3 minor criteria.
Patients with possible ARVC have 1 major criterion or 2
minor criteria. Athletes with borderline or possible ARVC,
as well as those who are genotype positive–phenotype
negative, should receive continued follow-up, because
ARVC may progress phenotypically, and become more
clinically apparent with time.
There is evidence in the experimental murine model
that exercise increases the penetrance and arrhythmic
risk in mutational carriers of ARVC (59). More recently,these data have been conﬁrmed in genetically positive
patients (60), which is particularly relevant to the athlete,
raising concern not only with regard to competitive sports
but also regarding participation in moderate to extreme
recreational physical activities.
Ventricular tachyarrhythmias and sudden death in
ARVC commonly occur during exertion, including
competitive sports (55,60,61), and frequent endurance
exercise increases the risk for ventricular tachycardia/
ventricular ﬁbrillation and heart failure (60). However,
risk factors for sudden cardiac death in ARVC are not
as well deﬁned as in HCM (1,2,7,8). There is general
agreement that a prior history of sudden cardiac death,
sustained ventricular tachycardia, or syncope represent
the most important prognostic factors and deﬁne many
high-risk patients who are most appropriately treated
with a primary prevention ICD (62–64).
Recommendations
1. Athletes with a deﬁnite diagnosis of ARVC should not
participate in most competitive sports, with the
possible exception of low-intensity class 1A sports
(Class III; Level of Evidence C).
2. Athletes with a borderline diagnosis of ARVC should
not participate in most competitive sports, with the
possible exception of low-intensity class 1A sports
(Class III; Level of Evidence C).
3. Athletes with a possible diagnosis of ARVC should not
participate in most competitive sports, with the
possible exception of low-intensity class 1A sports
(Class III; Level of Evidence C).
4. Prophylactic ICD placement in athlete-patients with
ARVC for the sole or primary purpose of permitting
participation in high-intensity sports competition is
not recommended because of the possibility of device-
related complications (Class III; Level of Evidence C).
Other recommendations for sports participation in pa-
tients with ARVC and ICDs can be found in the Task Force 9
report on “Arrhythmias and Conduction Defects” (23).
PERICARDITIS
The causes of pericarditis/myopericarditis are varied and
are either infectious or noninfectious. The natural history
is incompletely resolved, although long-term prognosis
is generally favorable. The diagnosis of acute pericarditis
is typically based on clinical criteria: chest pain, pericar-
dial rub, ST-segment elevation, or new/worsening peri-
cardial effusion. This syndrome may be considered part
of the clinical spectrum of myocarditis. Recurrences are
a signiﬁcant consideration, and follow-up surveil-
lance with echocardiography or CMR is recommended to
exclude pericardial thickening or restriction consistent
with restrictive pericarditis (50).
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1. Athletes with pericarditis, regardless of its patho-
genesis, should not participate in competitive
sports during the acute phase. Such athletes can
return to full activity when there is complete
absence of evidence for active disease, including
effusion by echocardiography, and when serumWriting Group Disclosures
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